Applications published 20 May 2009

Polymer systems for lung volume reduction therapy
Aeris Therapeutics 2059227*

Topical use of peptide extract of soybean and/or wheat as photoprotective agent
Thorel, Jean-Noel 2059230*

Pharmaceutical compsns comprising cefquinome
Intervet International BV 2059231*

Use of polyols to obtain stable polymorphous forms of rifamixin
Alfa Wassermann 2059232*

Inhibitors of proetin phosphatase 1, GADD34 and protein phosphatase 1/GADD34 complex, preparation and uses thereof
Institut Gustave Roussy; INSERM (Institut National de la Sante et de la Recherche Medicale) 2059233*

• Method for reducing or alleviating inflammation in the digestive tract
Ore Pharmaceuticals 2059234*

• Method for prevention and treatment of Alzheimer's
Toppo, Frank; Toppo, Robert 2059235*

• Combination with bis(thiohydrazide amides) for treating cancer
Synta Pharmaceuticals 2059236*

• Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
Parion Sciences 2059237*

• Therapeutic compounds for diseases and disorders
Myriad Genetics 2059238*

• Enhanced mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
Parion Sciences 2059239*

• Novel compsn and method effective in inhibiting the atherogenic process
Rath, Matthias 2059240*

• Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
Schering 2059241*

• Methods of lowering glucose levels
Sanofi-Aventis Deutschland 2059242*

• Buprenophine-wafer for drug substitution therapy
Euro-Celtique 2059243*

• Titration schedule for bifeprunox for treating schizophrenia and kits for use therein
Solvay Pharmaceuticals 2059244*

• Bifeprunox doses for treating schizophrenia
Solvay Pharmaceuticals; H Lundbeck 2059245*

• Therapeutic compsns comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Actelion Pharmaceuticals 2059246*

• Method and compsn for promoting gastrointestinal bicarbonate secretion
Sucampo 2059247*

• Pharmaceutical preparation for the alleviation of endometriosis
Bayer Schering Pharma 2059248*

• Pharmaceutical compsns for the treatment of inflammation or obstructive airway diseases
Novartis 2059249*

• Compounds for the treatment of angiogenesis
Synta Pharmaceuticals 2059250*

• Use of an unactivated calcium exchanged zeolites in hemostatic devices and products
Honeywell 2059251*

• Birch bark pelletisation and methods for obtaining natural products from birch bark pellets
Naturnorth Technologies 2059252*

• Modulation of regulatory T cells by human IL-18
The Trustees of the University of Pennsylvania 2059253*

• Sensitisation of tumour cells to radiation therapy through the administration of endothelin agonists
Spectrum Pharmaceuticals; The Board of Trustees of the University of Illinois 2059254*

• HSV-1 and HSV-2 vaccines and methods of use thereof
The Trustees of the University of Pennsylvania 2059255*

• Immunogenic peptides and their use in immune disorders
Desire Collen Research Foundation 2059256*

• Use of glycolipids as adjuvants
Helmholtz-Zentrum fuer Infektionsforschung GmbH 2059257*

• Arginine wash in protein purification using affinity chromatography
Wyeth 2059258*

• Pharmaceutical compsns for the treatment of fungal infections
Novartis 2059259*

• Pharmaceutical compsns comprising hgh for oral delivery
Novartis 2059260*

• Method for the production of conjugates of insulin-like growth factor-I and poly(ethylene glycol)
F Hoffmann-La Roche 2059261*

• A DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein
Sungkyunkwan University Foundation for Corporate Collaboration 2059262*

• Use of light-sensitive genes
Novartis 2059263*

• Process for preparing N-methyladamantyl derivatives by a palladium catalysed coupling reaction
AstraZeneca 2059497*

• Treatment of cancer
Bipar Services 2059498*

• Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom
Aukland Uniservices 2059499*

• Inhibitors of zinc proteases thioaryl substituted and their use
Bracco Imaging 2059500*

• Process for oxidising alkylaromatic compounds
ExxonMobil Chemical Patents 2059501*

• Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation
Ligated Pharmaceuticals 2059502*

• Aminopyrazole derivatives, process for the preparation thereof, and compsn for preventing or treating ischaemic diseases containing the same
Korea Research Institute of Chemical Technology 2059503*

• 3-substituted-1,5-diaryl-2-alkylpyrroles highly selective and orally effective COX-2 inhibitors
Rottapharm 2059504*

• Muscarinic receptor antagonists
Ranbaxy Laboratories 2059505*

• Novel piperidine derivatives and their use as monoamine neurotransmitter reuptake inhibitors
NeuroSearch 2059506*

• EP2 agonists
Pfizer Products 2059507*

• 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists
Sanofi-Aventis 2059508*

• Process for the preparation of montelukast, and intermediates therefor
Cipla 2059509*

• Sox-based kinase sensor
Massachusetts Institute of Technology 2059510*

• Sulphoximides as protein kinase inhibitors
Bayer Schering Pharma 2059511*

• P38 kinase inhibitors
Praecis Pharmaceuticals 2059512*

• Processes for the preparation of 1,2,4-oxadiazole benzoic acids
PTC Therapeutics 2059513*

• Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
The Texas A&M University System 2059514*

• Pyrrolidine derivatives as modulators of chemokine CCR5 receptors
Pfizer 2059515*

• Pyridine compounds for treating GPR119 related disorders
Biovitrium 2059516*

• Pyrimidine compounds for treating GPR119 related disorders
Biovitrium 2059517*

• Salts of benzimidazolyl pyridyl ethers and formulations thereof
Novartis 2059518*

• Nitrogen-containing heterocyclic compounds and methods of use thereof
Schering 2059519*

• 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azuline derivatives as orexin receptor antagonists
Actelion Pharmaceuticals 2059520*

• Pyrazolo[1,5-A]pyrimidines, processes, uses and compsns
Ferrer International 2059521*

• Phosphonate and phosphinate compounds as glucokinase activators
Bristol-Myers Squibb 2059522*

• High pressure treatment of proteins for reduced immunogenicity
Barofold 2059523*

• Aquaretic and natriuretic polypeptides lacking vasodilatory activity
Mayo Foundation for Medical Education and Research 2059524*

• Split-core particles for the presentation of foreign molecules, especially for vaccine applications, and method for their production
Universitaetsklinikum Freiburg 2059525*

• Borrelia antigens
Intercell 2059526*

• Modified proteins
Novo Nordisk Health Care 2059527*

• Recombinant inteferon-beta with enhanced biological activity
Novartis 2059528*

• Screening method for GPCR ligands
Max-Planck-Gesellschaft zur Foerderung der Wissenschaften 2059529*

• Method for the production of insulin-like growth factor-I
F Hoffmann-La Roche 2059530*

• Small streptococcus pyogenes antigens and their use
Intercell 2059531*

• Human binding molecules capable of neutralising influenza virus H5N1 and uses thereof
Crucell Holland 2059532*